Bicard
RX

Bicard

Bicard

Bicard – tablets that are recommended for the treatment of patients with arterial hypertension, angina pectoris and chronic heart failure. The drug components have an effect that reduces oxygen consumption, heart rate and volumetric blood flow. Read more about the drug and its features in the instructions.

Information

Indications for use (instruction): Bicard

Arterial hypertension, coronary heart disease (angina pectoris), chronic heart failure with systolic dysfunction of the left ventricle in combination with ACE inhibitors, diuretics, and, if necessary, cardiac glycosides.

How to use

The drug Bikard® should be taken without chewing, in the morning on an empty stomach, during or after breakfast, with a small amount of liquid.

Arterial hypertension; coronary heart disease (angina pectoris).

Treatment should be started gradually with low doses followed by a dose increase. The recommended dose is 5 mg (1 tablet Bikard® 5 mg) per day. With a mild degree of hypertension (diastolic pressure up to 105 mm Hg), a dose of 2.5 mg is suitable.

If necessary, the daily dose can be increased to 10 mg (1 tablet Bicard® 10 mg) per day. A further increase in dose is justified only in exceptional cases. The maximum recommended dose is 20 mg per day.

The dose adjustment is set by the doctor individually depending on the pulse rate and therapeutic benefit.

Chronic heart failure with systolic dysfunction of the left ventricle in combination with ACE inhibitors, diuretics, and, if necessary, cardiac glycosides.

Standard therapy for chronic heart failure: ACE inhibitors (or angiotensin receptor blockers in case of intolerance to ACE inhibitors), ß-adrenoreceptor blockers, diuretics and, if necessary, cardiac glycosides.

Bicard® is prescribed for the treatment of patients with chronic heart failure without signs of exacerbation.

Therapy should be carried out by a doctor with experience in the treatment of chronic heart failure.

The treatment of stable chronic heart failure with Bicard® begins in accordance with the titration scheme below and can be adjusted depending on the individual reactions of the body.

  • 1.25 mg * bisoprolol fumarate 1 time per day for 1 week, if well tolerated, increase to
  • 2.5 mg * bisoprolol fumarate 1 time per day for the next 1 week, if well tolerated, increase to
  • 3.75 mg * bisoprolol fumarate 1 time per day for the next 1 week, if well tolerated, increase to
  • 5 mg bisoprolol fumarate once a day for the next 4 weeks, if well tolerated, increase to
  • 7.5 mg bisoprolol fumarate once a day for the next 4 weeks, if well tolerated, increase to
  • 10 mg bisoprolol fumarate once a day as maintenance therapy.

* At the beginning of therapy for chronic heart failure, it is recommended to use bisoprolol in a dose of 2.5 mg.

The maximum recommended dose of bisoprolol fumarate is 10 mg once a day.

During the titration phase, monitoring of the following vital signs (blood pressure, heart rate) and symptoms of progression of heart failure is necessary. Symptoms may develop from the first day after the start of treatment.

Treatment Modification.

If the maximum recommended dose is poorly tolerated, a gradual dose reduction is possible. If a gradual worsening of heart failure occurs during the titration phase or after it, arterial hypotension or bradycardia develops, a dose adjustment is recommended, which may require a temporary reduction in the dose of bisoprolol or, possibly, suspension of treatment. After stabilization of the patient's condition, consideration should always be given to the possibility of re-initiating treatment with bisoprolol.

You should not stop treatment with the drug suddenly, especially to patients with coronary heart disease, as this can lead to a deterioration in the patient's condition. If necessary, treatment is recommended to be completed slowly, gradually reducing the dose (for example, by halving the dose weekly).

Treatment for stable chronic heart failure is usually long.

The course of treatment of Bicard® is long and depends on the nature and severity of the disease.

Patients with hepatic and/or renal failure.

Arterial hypertension; coronary heart disease. For patients with impaired liver or kidney function of mild to moderate severity, dose selection usually does not need to be done. In patients with severe renal failure (creatinine clearance less than 20 ml / min) and in patients with severe hepatic insufficiency, the dose should not exceed a daily dose of 10 mg Bicard®. There is limited evidence for the use of bisoprolol in dialysis patients. There is no need to change the dosage regimen.

Chronic heart failure. There is no pharmacokinetics of bisoprolol in patients with chronic heart failure concurrently with impaired liver or kidney function, so increase the dose with caution.

Elderly patients do not require dose adjustment.

Children. Clinical data on the effectiveness and safety of the drug in children are not available, therefore, the drug should not be used in this category of patients.

Contraindications

  • acute heart failure or heart failure in a state of decompensation, which requires inotropic therapy;
  • cardiogenic shock;
  • blockade of the II and III degree (with the exception of this in patients with an artificial pacemaker);
  • sick sinus syndrome;
  • sinoatrial block;
  • symptomatic bradycardia;
  • symptomatic arterial hypotension;
  • severe form of bronchial asthma;
  • late stages of peripheral circulation disturbance or Raynaud's disease;
  • pheochromocytoma, which has not been treated;
  • metabolic acidosis;
  • hypersensitivity to bisoprolol or other components of the drug.

Composition

Active substance: bisoprolol;

1 tablet contains bisoprolol fumarate, respectively 5 mg or 10 mg.

Excipients: microcrystalline cellulose, corn starch, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, anhydrous sodium phosphate, hypromellose, titanium dioxide (E 171), polyethylene glycol 6000, yellow iron oxide (E 172).

Release form

15 tablets in a blister, 2 blisters in a cardboard box.

Dosage form. Film-coated tablets.

Basic physical and chemical properties:

  • for tablets with a dosage of 5 mg – tablets, film-coated, pale yellow, round, biconvex, with a notch;
  • for tablets with a dosage of 10 mg – tablets, film-coated yellow, round, biconvex, with a notch.

Storage conditions

Store in the original packaging at a temperature not exceeding 25 °C out of the reach of children.

Manufacturer

Laboratorios Normon, S.A., Ronda de Valdecarrizo, 6, Tres Cantos 28760 (Madrid) Spain.

Registration certificate

№799 dated 04/26/2018.

Information on medicines is intended exclusively for doctors.